Listed

Biocryst Pharmaceuticals Inc

BCRXNasdaqCIK 882796HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$218.3mRevenue, Q2 FY2026, three months to 2026-06-30$218.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 5, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$218.3mRevenue, Q2 FY2026, three months to 2026-06-30$218.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure+33.6% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin45.1%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $98.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Revenue: $218.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure+26.9 pts on a year earlier
  • Net margin35.9%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $78.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Revenue: $218.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure+32.8 pts on a year earlier
  • Diluted EPS$0.30Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure+1400.0% on a year earlier
  • Free cash flow$104.1mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $104.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001628280-26-053300. Derived: 6-month figure less the 3-month figure.Capital expenditure: $209.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-08-05, accession 0001628280-26-053300. Derived: 6-month figure less the 3-month figure.Report this figure+153.2% on a year earlier

Last eight quarters

Full statements
Revenue$218.3mOperating margin 45.1%
Diluted EPS$0.30, Q2 FY2026
Free cash flow$104.1m, Q2 FY2026
Biocryst Pharmaceuticals Inc, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m117Revenue, Q3 FY2024, three months to 2024-09-30$117.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure132Revenue, Q4 FY2024, three months to 2024-12-31$131.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure146Revenue, Q1 FY2025, three months to 2025-03-31$145.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure163Revenue, Q2 FY2025, three months to 2025-06-30$163.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure159Revenue, Q3 FY2025, three months to 2025-09-30$159.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure407Revenue, Q4 FY2025, three months to 2025-12-31$406.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure156Revenue, Q1 FY2026, three months to 2026-03-31$156.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure218Revenue, Q2 FY2026, three months to 2026-06-30$218.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%6.6%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $7.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Revenue: $117.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure(3.4%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$4.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Revenue: $131.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure14.6%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $21.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Revenue: $145.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure18.2%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $29.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Revenue: $163.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure18.6%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $29.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Revenue: $159.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure64.0%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $260.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Revenue: $406.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure(448.6%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$701.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Revenue: $156.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure45.1%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $98.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Revenue: $218.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Net margin%(12.0%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$14.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Revenue: $117.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure(20.4%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$26.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Revenue: $131.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure0.0%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $32.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Revenue: $145.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure3.1%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $5.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Revenue: $163.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure8.1%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $12.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Revenue: $159.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure60.5%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $245.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Revenue: $406.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure(461.5%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$721.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Revenue: $156.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure35.9%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $78.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Revenue: $218.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Diluted EPS$ per share(0.07)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figurenot reported (Diluted EPS not reported)0.00Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure0.02Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure0.06Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figurenot reported (Diluted EPS not reported)(2.98)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$2.98 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure0.30Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Free cash flow$m8.2Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $8.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001628280-25-048785. Derived: 9-month figure less the 6-month figure.Capital expenditure: $59.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-11-04, accession 0001628280-25-048785. Derived: 9-month figure less the 6-month figure.Report this figure(5.9)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Capital expenditure: $675.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure(27.7)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$27.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Capital expenditure: $143.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure41.1Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $41.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001628280-26-053300. Derived: 6-month figure less the 3-month figure.Capital expenditure: $179.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-08-05, accession 0001628280-26-053300. Derived: 6-month figure less the 3-month figure.Report this figure40.3Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $41.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001628280-25-048785. Derived: 9-month figure less the 6-month figure.Capital expenditure: $1.3m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-11-04, accession 0001628280-25-048785. Derived: 9-month figure less the 6-month figure.Report this figure291Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $292.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Capital expenditure: $802.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure(62.2)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$61.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Capital expenditure: $403.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure104Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $104.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001628280-26-053300. Derived: 6-month figure less the 3-month figure.Capital expenditure: $209.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-08-05, accession 0001628280-26-053300. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$874.8mOperating margin 39.0%
Diluted EPS$1.21, FY2025
Free cash flow$344.9m, FY2025
Biocryst Pharmaceuticals Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m157Revenue, FY2021, twelve months to 2021-12-31$157.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-02-27, accession 0001628280-24-007205.Report this figure271Revenue, FY2022, twelve months to 2022-12-31$270.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-02-25, accession 0001628280-25-007715.Report this figure331Revenue, FY2023, twelve months to 2023-12-31$331.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure451Revenue, FY2024, twelve months to 2024-12-31$450.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure875Revenue, FY2025, twelve months to 2025-12-31$874.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(113.1%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$177.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-27, accession 0001628280-24-007205.Revenue: $157.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-02-27, accession 0001628280-24-007205.Report this figure(54.8%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$148.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-25, accession 0001628280-25-007715.Revenue: $270.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-02-25, accession 0001628280-25-007715.Report this figure(31.3%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$103.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012240.Revenue: $331.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure(0.6%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012240.Revenue: $450.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure39.0%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $341.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012240.Revenue: $874.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure
Net margin%(117.1%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$184.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-27, accession 0001628280-24-007205.Revenue: $157.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-02-27, accession 0001628280-24-007205.Report this figure(91.2%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$247.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-25, accession 0001628280-25-007715.Revenue: $270.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-02-25, accession 0001628280-25-007715.Report this figure(68.4%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$226.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012240.Revenue: $331.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure(19.7%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$88.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012240.Revenue: $450.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure30.2%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $263.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012240.Revenue: $874.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure
Diluted EPS$ per share(1.03)Diluted EPS, FY2021, twelve months to 2021-12-31−$1.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-27, accession 0001628280-24-007205.Report this figure(1.33)Diluted EPS, FY2022, twelve months to 2022-12-31−$1.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-25, accession 0001628280-25-007715.Report this figure(1.18)Diluted EPS, FY2023, twelve months to 2023-12-31−$1.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure(0.43)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure1.21Diluted EPS, FY2025, twelve months to 2025-12-31$1.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure
Free cash flow$m(145)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$142.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-27, accession 0001628280-24-007205.Capital expenditure: $2.4m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2024-02-27, accession 0001628280-24-007205.Report this figure(163)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$161.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-25, accession 0001628280-25-007715.Capital expenditure: $1.4m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2025-02-25, accession 0001628280-25-007715.Report this figure(97.3)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$95.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012240.Capital expenditure: $2.2m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure(53.1)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$52.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012240.Capital expenditure: $1.1m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure345Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $347.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012240.Capital expenditure: $2.5m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Biocryst Pharmaceuticals Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$238.9m23,893,036Added+1,242,048
RA CAPITAL MANAGEMENT, L.P.2026-06-30$158.3m15,827,186Unchanged
STATE STREET CORP2026-06-30$151.9m15,191,098Added+2,982,738
DEERFIELD MANAGEMENT COMPANY, L.P.2026-06-30$151.0m15,096,403Added+58,403
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$113.6m11,364,236Added+228,474
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$111.4m11,139,158Reduced−105,467
TCG Crossover Management, LLC2026-06-30$110.2m11,020,968Unchanged
PERCEPTIVE ADVISORS LLC2026-06-30$103.1m10,308,888Added+2,874,855
Jupiter Topco LLC2026-06-30$95.3m9,540,764Not compared
JANUS HENDERSON GROUP PLC2026-03-31$84.9m8,908,506Not compared

Recent filings

All 1,542 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Biocryst Pharmaceuticals Inc, recent filings
FiledFormWhat it isAccession number
2026-08-0516:04 ET10-QQuarterly reportPeriod 2026-06-300001628280-26-053300
2026-08-0507:02 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001171843-26-005223
2026-08-0407:01 ET8-K/A2.05 Exit or disposal costs0001171843-26-005168
2026-06-2907:06 ET8-K2.05 Exit or disposal costs; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001171843-26-004333
2026-06-1216:10 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001171843-26-004096
2026-05-0616:06 ET10-QQuarterly reportPeriod 2026-03-310001628280-26-031238
2026-05-0607:08 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001171843-26-003052
2026-05-0407:06 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001171843-26-002960
2026-04-2316:02 ETDEF 14AProxy statementPeriod 2026-06-110001628280-26-026822
2026-02-2616:03 ET10-KAnnual reportPeriod 2025-12-310001628280-26-012240

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
882796
Tickers
BCRX
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:27 ET. Listed shows no prices and gives no investment advice.